Larry Latowsky is the new chief executive of Canntab Therapeutics Ltd.
The Toronto-based biopharmaceutical company has announced that co-founder, Jeff Renwick, is to assume the role of company president and head of manufacturing as he passes down the CEO torch to Latowsky.
“Making room for a person of Larry’s experience was an easy decision,” Renwick said in a statement. “Our commitment is to build a world-class company and that begins by attracting world-class talent.”
In early March, Canntab originally announced Latowsky as executive chairman of its board of directors. In a press release, CFO Richard Goldstein said the company is looking to Latowsky to lead its commercialization strategy with an emphasis on distribution channels around the world.
According to a company statement on Aug. 19, the board of directors unanimously decided that Latowsky’s expertise would be much more suited for a full-time role as CEO.
Latowsky has gained experience leading major brands in the Canadian pharmaceutical space. Most recently, he served as CEO of Katz Group Canada, which owns and operated a network of leading pharmacies that includes Recall, Pharmaplus, IDA and Guardian Drugstores. Latowsky also led Propharm Technology and DC Labs a vertical manufacturing and packaging division of pharmaceuticals and over the counter drug store product.
“I am very excited to join Canntab on a full-time basis,” said Latowsky in a statement. “Canntab’s IP and product offerings are truly unique. There is a tremendous opportunity for Canntab’s products both within Canada and worldwide.”
Print this page